CFO
Kevin Feeley is the Chief Financial Officer at GeneDx Holdings Corp., a role he has held since August 2022, where he leads financial strategy, management, planning, and key operational areas including lab network operations, supply chain, and genetic counseling services.[[1]](https://www.marketscreener.com/insider/KEVIN-FEELEY-A3K948/)[[2]](https://www.genedx.com/leadership-team/kevin-feeley/)[[3]](https://www.genedx.com/leadership/kevin-feeley)[[6]](https://www.genedx.com/leadership) A Certified Public Accountant (CPA) with over 20 years of experience in finance and accounting within the healthcare, pharmaceutical, and diagnostics sectors, Feeley earned a BBA in Accounting from James Madison University.[[1]](https://www.marketscreener.com/insider/KEVIN-FEELEY-A3K948/)[[2]](https://www.genedx.com/leadership-team/kevin-feeley/)[[3]](https://www.genedx.com/leadership/kevin-feeley)
Prior to GeneDx, Feeley served as CFO of OPKO Health’s diagnostics division for six years, overseeing BioReference Laboratories, Inc. and GeneDx, and led BioReference’s sports diagnostic program during the COVID-19 pandemic for all four major U.S. sports leagues.[[1]](https://www.marketscreener.com/insider/KEVIN-FEELEY-A3K948/)[[2]](https://www.genedx.com/leadership-team/kevin-feeley/)[[3]](https://www.genedx.com/leadership/kevin-feeley) His earlier roles include CFO at Bio-Reference Laboratories, Inc., U.S. Controller at Reckitt Benckiser, leadership in SEC reporting at Bausch Health Companies, and 12 years in KPMG LLP’s audit practice with multinational pharmaceutical clients.[[1]](https://www.marketscreener.com/insider/KEVIN-FEELEY-A3K948/)[[2]](https://www.genedx.com/leadership-team/kevin-feeley/)[[3]](https://www.genedx.com/leadership/kevin-feeley) Recently, as a 10% owner and insider, he sold 377 shares of GeneDx Class A Common Stock on December 1, 2025, to cover tax obligations, with holdings valued at approximately $873,402 as of February 2025.[[1]](https://www.marketscreener.com/insider/KEVIN-FEELEY-A3K948/)[[4]](https://www.investing.com/news/insider-trading-news/feeley-genedx-cfo-sells-61276-in-wgs-stock-93CH-4389454)[[5]](https://www.tradingview.com/news/tradingview:76d30b970fb5c:0-genedx-holdings-corp-cfo-kevin-feeley-sells-shares-to-cover-tax-obligations/)
View full insider profile →
